An Open Label Phase 1/2 Study to Assess Immunogenicity and Safety of Different Dose Levels of H1N1 Pandemic Influenza Vaccine in Healthy Adults Aged 18 Years and Older
Phase of Trial: Phase I/II
Latest Information Update: 13 Oct 2015
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Baxter Healthcare Corporation
- 08 Jul 2010 Actual patient number (408) added as reported by ClinicalTrials.gov.
- 08 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Feb 2010 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.